Skip to main content

Table 1 Baseline characteristics of randomized participants in the SELEBLAT trial

From: Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium

Variable   Total 100
Gender [N (%)] Male [N (%)] 83 (83)
  Female 17 (17)
Age ≤ 50 yrs. [N (%)] 2 (2)
  51-60 [N (%)] 17 (17)
  61-70 [N (%)] 34 (34)
  71-80 [N (%)] 36 (36)
  > 80 [N (%)] 11 (11)
  Years [mean, (SD)] 68 (9)
Language [N (%)] Dutch 87 (87)
  French 13 (13)
Primary Primary 61 (60)
Tumour [N (%)] Recurrent 35 (35)
  Unknown 5 (5)
Tumour G1 31 (30)
Grade [N (%)] G2 35 (34)
  G3 33 (32)
  Unknown 4 (4)
Tumour pTa 60 (58)
Stage [N (%)] pT1 31 (30)
  Cis 5 (5)
  Unknown 7 (7)
Tumour Papillary 121 (79)
Type [N (%)] Cis 29 (19)
  Unknown 3 (2)
Tumour < 1 cm 59 (38)
Size [N (%)] ≥1 and ≤ 3 56 (37)
  > 3 cm 38 (25)
Tumour Solitary 59 (60)
Number [N (%)] 2 or more 36 (36)
  Unknown 4 (4)
Selenium ng/mL [mean, (SD)] 84.8 (18.5)